Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Malmström, Rickard E., Godman, Brian B., Diogene, Eduard, Baumgärtel, Christoph, Bennie, Marion, Bishop, Iain, Brzezinska, Anna, Bucsics, Anna, Campbell, Stephen, Ferrario, Alessandra, Finlayson, Alexander E., Fürst, Jurij, Garuoliene, Kristina, Gomes, Miguel, Gutiérrez-Ibarluzea, Iñaki, Haycox, Alan, Hviding, Krystyna, Herholz, Harald, Hoffmann, Mikael, Jan, Saira, Jones, Jan, Joppi, Roberta, Kalaba, Marija, Kvalheim, Christina, Laius, Ott, Langner, Irene, Lonsdale, Julie, Lööv, Sven-Äke, Malinowska, Kamila, McCullagh, Laura, Paterson, Ken, Markovic-Pekovic, Vanda, Martin, Andrew, Piessnegger, Jutta, Selke, Gisbert, Sermet, Catherine, Simoens, Steven, Tulunay, Cankat, Tomek, Dominik, Vončina, Luka, Vlahovic-Palcevski, Vera, Wale, Janet, Wilcock, Michael, Wladysiuk, Magdalena, van Woerkom, Menno, Zara, Corrine, Gustafsson, Lars L.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Frontiers Media S.A. 2013
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3653065/
https://ncbi.nlm.nih.gov/pubmed/23717279
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2013.00039
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi